3755-96-2

Upstream product

• 3755-97-3 β-bromo-trans-cinnamic acid amide 
• 506-68-3 bromocyane 
• 536-74-3 phenylacetylene 
• 60-29-7 diethyl ether 
• 10026-13-8 phosphorus pentachloride 
• 614-16-4 Benzoylacetonitrile 

Downstream Products

• 237435-85-7 3-amino-5-phenylfuran-2-carbonitrile 
• 1274654-71-5 (4Z)-3,4-diphenylhexa-2,4-diene-1,6-dinitrile 
• 1274654-72-6 4,5-diphenyl-5-(2,4-dimethoxyphenyl)pyrrol-2-one 
• 176445-14-0 (E)-3-(4-methylphenyl)-3-phenyl-2-propenenitrile 
• 1274654-70-4 (2Z)-3,5-diphenylpent-2-en-4-ynenitrile 
• 88534-50-3 ethyl 3-amino-5-(phenyl)thiophene-2-carboxylate 
• 1017242-73-7 (2Z)-4-oxo-3,4-diphenylbut-2-en-carbonitrile 
• 3755-97-3 β-bromo-trans-cinnamic acid amide 
• 1823-99-0 3-amino-3-phenylacrylonitrile 

Relevant academic research and scientific papers

Gallium (iii)-catalysed bromocyanation of alkynes: Regio- and stereoselective synthesis of β-bromo-α,β-unsaturated nitriles

Treatment of arylacetylenes and cyanogen bromide in ClCH2CH 2Cl with a catalytic amount of GaCl3 afforded (Z)-β-bromoacrylonitriles with high regio- and stereoselectivity.

Compounds and methods which modulate feeding behavior and related diseases

There are provided compounds, compositions and methods of use thereof in the modulation of feeding behavior, obesity, diabetes, cancer (tumor), inflammatory disorders, depression, stress related disorders, Alzheimer's disease and other disease conditions.

Structure-activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists

Neuropeptide Y (NPY) has been shown to play an important role in the regulation of food intake and energy balance. Pharmacological data suggests that the Y5 receptor subtype contributes to the effects of NPY on appetite, and therefore a Y5 antagonist might be a useful therapeutic agent for the treatment of obesity. In attempts to identify potential Y5 antagonists, a series of pyrrolo[3,2-d]pyrimidine derivatives was prepared and evaluated for their ability to bind to Y5 receptors in vitro. We report here the synthesis and initial structure-activity relationship investigations for this class of compounds. The target compounds were prepared by a variety of synthetic routes designed to modify both the substitution and the heterocyclic core of the pyrrolo[3,2-d]pyrimidine lead 1. In addition to identifying several potent Y5 antagonists for evaluation as potential antiobesity agents, a pharmacophore model for the human Y5 receptor is presented.